In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KAI Pharmaceuticals

http://www.kaipharma.com

Latest From KAI Pharmaceuticals

Financing Quarterly Statistics, Q3 2022

During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.

Deals Financing

Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority

NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.

Clinical Trials Business Strategies

Bayer’s Vividion Looks To Tavros For Precision Targeting In Cancer

Deal Snapshot: Vividion hopes Tavros’s functional and computational genomics technology will help it discover and validate novel targets in precision oncology therapy.

Deals Business Strategies

AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope

Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.

Gene Therapy FDA
See All

Company Information

UsernamePublicRestriction

Register